GSK’s herpes zoster vaccine, Shingrix, has been granted a registration certificate by the Ministry of Health of Russia. The information is published in the State Register of Medicines.
Clinical studies have demonstrated that the utilization of the vaccine significantly decreases the likelihood of developing herpes zoster by an impressive 97.2% when compared to a placebo. As shown, the drug remains highly effective irrespective of the patient’s age. Thus, in the age group 50-59 years old it was 96.6%, 60-69 years old – 97.4%, and among people over 70 years old – 98%. The vaccine contains the viral protein gE and an adjuvant system to enhance the immunological response.